Fig. 1 · Structure

Documents & Downloads

CHIR-124

Cat. No. A11046 CAS 405168-58-3

CHK Inhibitor

CHIR-124 is a novel and potent Chk1 inhibitor (IC50: 0.32 nM and 697 nM for Chk1 and Chk2 respectively).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Chk1 IC50 0.3nM
FLT3 IC50 5.8nM
PDGFR IC50 6.6nM
GSK-3 IC50 23.3nM
Fyn IC50 98.8nM
PKA IC50 103.1nM
PKCγ IC50 110nM
LCK IC50 158.3nM
CDK2/CyclinA IC50 191.1nM
VEGFR1/FLT1 IC50 463.6nM
Cdc2/CyclinB IC50 505.7nM
VEGFR2/Flk1 IC50 577.9nM
PKCβ2 IC50 580nM
PKCα IC50 580nM
Chk2 IC50 697.4nM
FGFR3 IC50 1.29μM
bFGFR IC50 2.04μM
CDK4/CyclinD IC50 2.05μM
PKAβ1 IC50 2.25μM
c-Met IC50 >3μM
ERK2 IC50 4.31μM
CABL IC50 14.88μM

22 targets · Scroll to view more

In Vitro Studies

In vitro asexual blood stage cultures treated with the tested compound showed dose-dependent growth inhibition. In MDA-MB-231 cells, treatment consistently reduced BRCA1 protein levels, as assessed by Western blots with quantitation. In parental IGR-CaP1 cells, treatment at 100 nM was associated with an 83% decrease in the ability to form colonies. Immature gametocytes in in vitro cultures were treated with the study compound and showed dose-dependent growth inhibition. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Dose-dependent growth inhibition in asexual blood stage cultures

Cell-based study · Asexual blood stage (ABS, PfNF54) [1]

In vitro asexual blood stage cultures treated with the tested compound showed dose-dependent growth inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
dose-dependent growth inhibitionIC50 0.14 ± 0.03 μM[1]

Literature-Reported Treatment Conditions

Method
in vitro cultures
Reported limits
Not stated in the sentences used: dose, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: CHIR-124

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > CHIR-124 Identified via Kinobead Assays with Multistage Antiplasmodial Activity (S10); 1 (T1.h1, T1.r1)

dose-dependent growth inhibition: dose-dependent growth inhibition — Results > CHIR-124 Identified via Kinobead Assays with Multistage Antiplasmodial Activity (S10); 1 (T1.h1, T1.r1)

Consistent BRCA1 Protein Downregulation

Cell-based study · MDA-MB-231 cells [2]

In MDA-MB-231 cells, treatment consistently reduced BRCA1 protein levels, as assessed by Western blots with quantitation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BRCA1 Western blots with quantitationReported result consistent downregulation of BRCA1 protein levels[2]

Literature-Reported Treatment Conditions

Reported limits
Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: CHIR-124

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Candidate compounds downregulate breast cancer susceptibility gene protein expression in MDA-MB-231 cells (S110, S111); Figure 7 legend (S328)

BRCA1 Western blots with quantitation: BRCA1 Western blots with quantitation — Results > Candidate compounds downregulate breast cancer susceptibility gene protein expression in MDA-MB-231 cells (S111); Figure 7 legend (S328)

Reduced Colony Formation in Parental IGR-CaP1 Cells

Cell-based study · parental IGR-CaP1 cells [3]

In parental IGR-CaP1 cells, treatment at 100 nM was associated with an 83% decrease in the ability to form colonies.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ability of cells to form coloniescolony formation 83% decrease[3]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
Eight to 10 days later
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route, control.
Methods and source locations

Compound reported in the paper: CHIR-124

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Targeting the CDC25C-interacting kinase CHEK1 to overcome Docetaxel resistance (S54, S60); MATERIALS AND METHODS > Cell culture, selection of Docetaxel-resistant clones and reagents (S70); MATERIALS AND METHODS > Foci formation assays (S111, S112)

ability of cells to form colonies: ability of cells to form colonies — RESULTS > Targeting the CDC25C-interacting kinase CHEK1 to overcome Docetaxel resistance (S60)

Dose-dependent growth inhibition in immature gametocytes

Cell-based study · Immature gametocytes (PfNF54) [1]

Immature gametocytes in in vitro cultures were treated with the study compound and showed dose-dependent growth inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
dose-dependent growth inhibitionIC50 3.1 ± 0.7 μM[1]

Literature-Reported Treatment Conditions

Method
in vitro cultures
Reported limits
Not stated in the sentences used: dose, schedule, vehicle, control.
Methods and source locations

Compound reported in the paper: CHIR-124

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > CHIR-124 Identified via Kinobead Assays with Multistage Antiplasmodial Activity (S10); 1 (T1.h1, T1.r2)

dose-dependent growth inhibition: dose-dependent growth inhibition — Results > CHIR-124 Identified via Kinobead Assays with Multistage Antiplasmodial Activity (S10); 1 (T1.h1, T1.r2)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 405168-58-3
Applications CHK Inhibitor
Formula C23H22ClN5O
Molecular Weight 419.9
SMILES
C1CN2CCC1[C@@H](C2)NC3=C4C=C(C=CC4=NC(=O)C3=C5NC6=CC=CC=C6N5)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 6 mg/mL (14.29 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wicht KJ, Woodland JG, Garnie LF, et al. The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of PfArk1 and Hemozoin Formation. ACS Chem Biol (2026). PMID: 42287204 DOI: 10.1021/acschembio.6c00264 Source material
  2. [2] Sellars E, Savguira M, Wu J, et al. A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity. iScience (2024). PMID: 38993666 DOI: 10.1016/j.isci.2024.110180 Source material
  3. [3] Al Nakouzi N, Cotteret S, Commo F, et al. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget (2014). PMID: 24525428 DOI: 10.18632/oncotarget.1574 Source material

Added to your cart

View Cart Checkout
Loading...